Elicio Therapeutics - Public Comps and Valuation Multiples

Elicio Therapeutics Overview

About Elicio Therapeutics

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Founded

2011

HQ

Employees

Website

elicio.com

Sectors

Drug Development & Therapeutics
Vaccines & Immunotherapies
BioTech

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$89.0M

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Elicio Therapeutics Financials

Elicio Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Elicio Therapeutics achieved revenue of n/a and an EBITDA of -$50.3M.

Elicio Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Elicio Therapeutics valuation multiples based on analyst estimates

Elicio Therapeutics P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	n/a	n/a	XXX	XXX	XXX
Gross Profit	n/a	n/a	XXX	XXX	XXX
Gross Margin	NaN%	NaN%	XXX	XXX	XXX
EBITDA	-$33.0M	-$50.3M	XXX	XXX	XXX
EBITDA Margin	-Infinity%	-Infinity%	XXX	XXX	XXX
Net Profit	-$28.2M	-$35.2M	XXX	XXX	XXX
Net Margin	-Infinity%	-Infinity%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Elicio Therapeutics Stock Performance

As of April 23, 2025, Elicio Therapeutics's stock price is $5.

Elicio Therapeutics has current market cap of $80.6M, and EV of $89.0M.

See Elicio Therapeutics trading valuation data

Elicio Therapeutics Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$89.0M	$80.6M	XXX	XXX	XXX	XXX	$-3.68

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Elicio Therapeutics Valuation Multiples

As of April 23, 2025, Elicio Therapeutics has market cap of $80.6M and EV of $89.0M.

Elicio Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Elicio Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Elicio Therapeutics and 10K+ public comps

Elicio Therapeutics Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$89.0M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	XXX	XXX
EV/EBITDA	-1.8x	XXX	XXX	XXX
P/E	-1.6x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	-2.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Elicio Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Elicio Therapeutics Valuation Multiples

Elicio Therapeutics's NTM/LTM revenue growth is n/a

Elicio Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.4M for the same period.

Over next 12 months, Elicio Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Elicio Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Elicio Therapeutics and other 10K+ public comps

Elicio Therapeutics Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	n/a	XXX	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	XXX	XXX	XXX
EBITDA Growth	52%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	n/a	XXX	XXX	XXX	XXX
Opex per Employee	$1.4M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
Opex to Revenue	n/a	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Streaming Platforms

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Explore Valuation Multiples by Industry